Development of a Polymeric Pharmacological Nanocarrier System as a Potential Therapy for Spinocerebellar Ataxia Type 7
Spinocerebellar ataxia type 7 (SCA7) is an autosomal-dominant inherited disease characterized by progressive ataxia and retinal degeneration. SCA7 belongs to a group of neurodegenerative diseases caused by an expanded CAG repeat in the disease-causing gene, resulting in aberrant polyglutamine (polyQ...
Main Authors: | Fabiola V. Borbolla-Jiménez, Ian A. García-Aguirre, María Luisa Del Prado-Audelo, Oscar Hernández-Hernández, Bulmaro Cisneros, Gerardo Leyva-Gómez, Jonathan J. Magaña |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/23/2735 |
Similar Items
-
New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors
by: Fabiola V. Borbolla-Jiménez, et al.
Published: (2021-07-01) -
Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
by: Huang DS, et al.
Published: (2016-02-01) -
Research progress of spinocerebellar ataxia type 1
by: Lin-wei ZHANG, et al.
Published: (2014-05-01) -
Spinocerebellar Ataxia 27: A Review and Characterization of an Evolving Phenotype
by: Christopher L. Groth, et al.
Published: (2018-01-01) -
Professor Wadia’s contributions to neurology and spinocerebellar ataxia type 2
by: Fernando Spina Tensini, et al.